The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

To evaluate the efficacy and safety of degarelix, a new gonadotrophin‐releasing hormone (GnRH) antagonist (blocker), vs leuprolide for achieving and maintaining testosterone suppression in a 1‐year phase III trial involving patients with prostate cancer.

[1]  M. Laudat,et al.  Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate. , 1986, European urology.

[2]  B. Tombal,et al.  Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. , 2008, European urology.

[3]  B. Tombal,et al.  How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard®? , 2005 .

[4]  R. Sharifi,et al.  Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. , 2002, The Journal of urology.

[5]  I. Thompson,et al.  Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. , 1990, The Journal of urology.

[6]  J. Moul,et al.  Combination hormonal therapy: a reassessment within advanced prostate cancer , 2004, Prostate Cancer and Prostatic Diseases.

[7]  J. Huirne,et al.  Gonadotropin-releasing-hormone-receptor antagonists , 2001, The Lancet.

[8]  E. Ben-Josef,et al.  Humoral mechanisms in prostate cancer:: A role for FSH , 2001 .

[9]  B. Tombal,et al.  How good do current LHRH agonists LHRH agonists control testosterone? - Can this be improved with Eligard (R) ? , 2005 .

[10]  R. Santen.  Clinical review 37: Endocrine treatment of prostate cancer. , 1992, Journal of Clinical Endocrinology and Metabolism.

[11]  H. Lepor.  Comparison of single-agent androgen suppression for advanced prostate cancer. , 2005, Reviews in urology.

[12]  V. Hasselblad,et al.  Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma , 2002, Cancer.

[13]  Z. Petrovich,et al.  Treatment of metastatic carcinoma of the prostate. , 1997, American journal of clinical oncology.

[14]  N. Zinner,et al.  Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. , 2004, Urology.

[15]  A. Orsola,et al.  Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. , 2007, The Journal of urology.

[16]  J. Bidart,et al.  Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). , 1999, The Journal of urology.

[17]  W. Crowley,et al.  Gonadotropin-releasing hormone and its analogues. , 1991, The New England journal of medicine.

[18]  R. Berges,et al.  Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer , 2006, Current medical research and opinion.

[19]  F. Debruyne,et al.  Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. , 2006, Future oncology.

[20]  B. Persson,et al.  A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. , 2008, The Journal of urology.

[21]  World Medical Association (WMA),et al.  Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects , 2009, Journal of the Indian Medical Association.

[22]  W F Hendry,et al.  Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. , 1985, British medical journal.

[23]  N. Nonomura,et al.  Skin Reactions to 3-month Depot Type of Luteinizing Hormone-Releasing Hormone Agonist Therapy , 2006 .